Volume 17 (2020)
Volume 16 (2019)
Volume 15 (2018)
Volume 14 (2017)
Volume 13 (2016)
Volume 12 (2015)
Volume 11 (2014)
Volume 10 (2013)
Volume 9 (2012)
Volume 8 (2011)
Volume 7 (2010)
Volume 6 (2009)
Volume 5 (2008)
Volume 4 (2007)
Volume 3 (2006)
Volume 2 (2005)
Volume 1 (2004)
Original Article
1. Immunoexpression of C4 Binding Protein in Oral Leukoplakia and Oral Squamous Cell Carcinoma

Fatemeh Mashhadi-Abbas; Masoume Fayazi_Boroujeni; Akram Alizadeh; Mahshid Namdari; Seyed Abbas Mirzaei

Volume 18, Issue 2 , Spring 2021, Pages 95-102

http://dx.doi.org/10.22034/iji.2021.87031.1782

Abstract
  Background: The immune evasion of dysplastic cells plays an important role in suppressing the immune response and progression of malignancy. The role of the complement inhibitors in the development of oral epithelial dysplastic lesions and squamous cell carcinoma (SCC) is still unclear. Objective: This ...  Read More

Short Paper
2. VEGF-A, HGF and bFGF are involved in IL-17A-mediated migration and capillary-like vessel formation of vascular endothelial cells

Muneo Numasaki; Koyu Ito

Volume 18, Issue 2 , Spring 2021, Pages 103-110

http://dx.doi.org/10.22034/iji.2021.91214.2059

Abstract
  Background: Interleukin (IL)-17A possesses biological activities to promote vascular endothelial cell migration and microvessel development. Objective: To clarify which angiogenic factors are involved in IL-17A-modified angiogenesis-related functions of vascular endothelial cell migration and microtube ...  Read More

Original Article
3. Diospyros peregrina fruit preparation mediated immunomodulation of lymphocytes isolated from the blood of breast cancer patients

Ahana Roy; Aitijhya Ghosh; Kasturi Sinha; Basundhara Mitra; Sudeshna Rakshit; Melvin George; Koustav Sarkar

Volume 18, Issue 2 , Spring 2021, Pages 111-118

http://dx.doi.org/10.22034/iji.2021.85430.1710

Abstract
  Background: Breast cancer is an uncontrolled growth of epithelial cells. The loss of BRCA1 activity due to mutation or down-regulation of gene expression promotes tumorigenesis and increases the risk of breast cancer. Objectives: Our aim was to pulsate lymphocytes of breast cancer patients and normal ...  Read More

Original Article
4. Effect of bortezomib regimens and daratumumab monotherapy on cellular immunity in multiple myeloma patients

Ashraf Kakoo; Taban Rasheed; Mustafa Al-Attar

Volume 18, Issue 2 , Spring 2021, Pages 119-129

http://dx.doi.org/10.22034/iji.2021.87547.1812

Abstract
  Background: Treatment with Bortezomib (a proteasome inhibitor) and Daratumumab (DARA, a monoclonal anti CD38 antibody) are effective in patients with multiple myeloma (MM). However, these drugs impair cellular immunity, which may render the patients more prone to infection. Objective: To investigate ...  Read More

Original Article
5. IL-17 Genetic Variations Increase the Risk of Cirrhotic/Hepatocellular Carcinoma in Patients with Hepatitis B Virus Infection.

Abolfazl Gheshlaghi; Mohammad Reza Haghshenas; Ali Reza Safarpour; Seyed Younes Hossini; Seyed Ali Malekhosseini; Mohammad Reza Fattahi; Jamal Sarvari

Volume 18, Issue 2 , Spring 2021, Pages 130-140

http://dx.doi.org/10.22034/iji.2021.88020.1852

Abstract
  Background: Genetic variation in immune regulatory genes might influence the HBV infection outcome. Objective: This study aimed to determinethe association of IL-17A rs2275913 (G197A), IL-17F rs763780 (A7488G), and IL-23R rs10889677 (C2370A) gene polymorphisms, as well as the emerged haplotypes in the ...  Read More

Original Article
6. Recombinant Production and One Step Purification of IL-1Ra in Escherichia coli and Evaluation its IL-1 Antagonizing Efficacy

Roya Adelnia; Fatemeh Shafiee

Volume 18, Issue 2 , Spring 2021, Pages 141-149

http://dx.doi.org/10.22034/iji.2021.89103.1929

Abstract
  Background: Anakinra (Kineret®), an IL-1 receptor antagonist, is the first FDA approved biologic drug for antagonizing IL-1 effects in patients with Rheumatoid arthritis. Notably, the less expensive production of this drug might help reduce the final therapeutic costs. Objectives: This study aimed ...  Read More

Case Report
7. Camrelizumab plus zoledronic acid showed sustained efficacy in a patient with cranial and spinal metastases from lung adenocarcinoma

Chu Zhang; Guangmao Yu; Miao Zhang; Wenbin Wu

Volume 18, Issue 2 , Spring 2021, Pages 150-157

http://dx.doi.org/10.22034/iji.2021.87760.1828

Abstract
  The role of anti-programmed cell death protein-1 (PD-1) antibody camrelizumab in brain metastases (BMs) from lung adenocarcinoma is uncertain. Herein, for the first time, we report the efficacy of camrelizumab in a patient with chemotherapy-refractory BMs from lung adenocarcinoma. A 49-year-old male ...  Read More

Case Report
8. High level of IgG4 in a patient with Extensive pulmonary involvement

Mohammad Hasan Bemanian; Sima Bahrami; Saba Arshi; Afshin Rezaeifar; Mohammad Nabavi; Morteza Fallahpour; Sima Shokri

Volume 18, Issue 2 , Spring 2021, Pages 158-162

http://dx.doi.org/10.22034/iji.2021.88789.1907

Abstract
  Immunoglobulin G4-Related Disease (IgG4-RD) is a systemic fibro-inflammatory disease that has been proposed as a separate entity since thebeginning of this century. The disease is often manifested by increasedserum IgG4 levels and certain histopathological manifestations. The patientmentioned in this ...  Read More

Case Report
9. Differential diagnosis from isolated lymphoid extramedullary blast crisis from secondary non-Hodgkin lymphoma in chronic myelogenous leukemia: a case report and literature review

Tingting Wang; Li Fu; Na Wei; Xiaoge Zhou; Xiaodan Zheng; Li Li; Zhao Wang

Volume 18, Issue 2 , Spring 2021, Pages 163-169

http://dx.doi.org/10.22034/iji.2021.84496.1661

Abstract
  Case: Extramedullary blast crisis (EBC) is a special kind of blast crisis of chronic myelogenous leukemia (CML). It is more likely to be misdiagnosed as lymphoma when EBC cells are of lymphoid cell lineage and lymphadenopathy is the only symptom before the final diagnosis. In this study, we presented ...  Read More